RISK EVALUATION AND MITIGATION STRATEGY (REMS)

I. GOAL(S):
The goal of the BLINCYTO REMS is to mitigate the risk of cytokine release syndrome which may be life-threatening or fatal; the risk of neurological toxicities which may be severe, life-threatening, or fatal; and the risk of preparation and administration errors associated with use of BLINCYTO by:

- Informing healthcare providers about the risk of cytokine release syndrome which may be life-threatening or fatal
- Informing healthcare providers about the risk of neurological toxicities which may be severe, life-threatening, or fatal
- Informing pharmacists, who will prepare and dispense BLINCYTO, and nurses, who will administer BLINCYTO, about the risk of preparation and administration errors associated with use of BLINCYTO.

II. REMS ELEMENTS
A. Communication Plan
Amgen will implement the following communication plan for healthcare providers who are likely to prescribe or dispense BLINCYTO. The communication plan will consist of the following:

1. REMS Letters
Amgen will send a REMS Letter for Healthcare Providers, a REMS Letter for Hospital and Home Healthcare Pharmacists, and a REMS Letter for Professional Societies within 30 days of the REMS approval date and every 6 months for 18 months. The REMS Letters will address the risk of cytokine release syndrome which may be life-threatening or fatal; the risk of neurological toxicities which may be severe, life-threatening, or fatal; and the risk of preparation and administration errors associated with use of BLINCYTO. Email will be used as the primary method to disseminate the REMS Letters. If an email is marked as unopened, a second email will be sent
within 30 calendar days of the date the first email was sent. If the second email is marked as unopened, the REMS Letters will be mailed within 30 calendar days of the date the second email was sent. If a healthcare provider’s or professional society’s email address is not available or if the email is undeliverable, the REMS Letters will be mailed within 30 calendar days of the date of the bulk mailing. A link to the Prescribing Information (PI) and REMS Fact Sheet will accompany each REMS Letter.

- **REMS Letter for Healthcare Providers:** The intended audience for the REMS Letter for Healthcare Providers will be oncologists, oncology physician assistants, oncology nurse practitioners, hematologists, oncology nurses, home healthcare oncology nurses, and infusion nurses likely to administer BLINCYTO.

- **REMS Letter for Hospital and Home Healthcare Pharmacists:** The intended audience for the REMS Letter for Hospital and Home Healthcare Pharmacists will be hospital-based pharmacists and home healthcare pharmacists.

- **REMS Letter for Professional Societies:** Amgen will send the REMS Letter for Professional Societies to the following professional societies requesting the letter or content be provided to their membership:
  - American Society of Clinical Oncology (ASCO)
  - American Society of Hematology (ASH)
  - Oncology Nursing Society (ONS)
  - National Comprehensive Cancer Network (NCCN)
  - Hematology Oncology Pharmacy Association (HOPA)
  - American Pharmacists Association (APhA)
  - American Society of Health System Pharmacists (ASHP)
  - Home Health Nurses Association (HHA)
  - National Association for Home Care & Hospice (NAHCH)
  - Advanced Practitioner Society for Hematology and Oncology (APSHO)

2. **REMS Fact Sheet for Providers:** A BLINCYTO REMS Fact Sheet for Providers will be made available for healthcare providers and distributed by Amgen’s sales representatives and medical field-based personnel during initial visits with healthcare providers for the first 12 months after the approval of the BLINCYTO REMS. Amgen’s field based sales or medical representatives will discuss the risk messages contained in the Fact Sheet during the visit with the healthcare provider.

3. **Dissemination of REMS information at Scientific Meetings:** The BLINCYTO REMS materials will be prominently displayed at relevant scientific meetings where Amgen has a presence (e.g., exhibit booth) through 18 months following the REMS approval.
4. **BLINCYTO REMS Website:** The BLINCYTO REMS website for healthcare providers (www.blincytoplems.com) will continue for the duration of the REMS. The BLINCYTO REMS website will include the option to print the PI, Medication Guide, Important Safety Information, REMS Letter for Healthcare Providers, and the REMS Fact Sheet. The BLINCYTO website for healthcare providers will include a prominent REMS-specific link to the BLINCYTO REMS website.

The following are part of the BLINCYTO REMS and are appended:

- *REMS Letter for Healthcare Providers* (email and print versions)
- *REMS Letter for Hospital and Home Healthcare Pharmacists* (email and print versions)
- *REMS Letter for Professional Societies* (email and print versions)
- *BLINCYTO REMS Fact Sheet for Providers*
- *BLINCYTO REMS Website* (landing page)

**III. Timetable for Submission of Assessments**

Amgen will submit REMS Assessments to the FDA at 18 months, 3 years, and 7 years from the date of approval of the initial REMS. To facilitate inclusion of as much information as possible while allowing reasonable time to prepare the submission, the reporting interval covered by each assessment should conclude no earlier than 60 days before the submission date for that assessment. Amgen will submit each assessment so that it will be received by the FDA on or before the due date.